Trial Profile
Clinical study on of combination therapy with a DPP-4 inhibitor and a mitiglinide/voglibose fixed-dose combination (the combination) on glycemic/metabolic responses after meals in patients with type 2 diabetic mellitus (T2DM)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Jun 2016
Price :
$35
*
At a glance
- Drugs Mitiglinide/voglibose (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 28 Oct 2015 New trial record